ストックスクリーナーアプリを入手
13.41
1.26%
0.1447
前日終値:
$13.27
開ける：
$13.36
24時間の取引高:
916.22K
Relative Volume:
0.83
時価総額：
$765.61M
収益：
-
当期純損益:
$-52.79M
株価収益率:
-17.22
EPS:
-0.7789
ネットキャッシュフロー:
$-53.49M
1週間 パフォーマンス:
+3.05%
1か月 パフォーマンス:
+27.37%
6か月 パフォーマンス:
+219.94%
1年 パフォーマンス:
+966.47%
1日の値動き範囲:
$12.84
$13.71
1週間の範囲:
$12.34
$14.41
52週間の値動き範囲:
$1.21
$14.41
Climb Bio Inc Stock (CLYM) Company Profile
Compare CLYM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
13.37 | 759.88M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | Mizuho | Outperform |
| 2026-03-24 | 開始されました | B. Riley Securities | Buy |
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-03-11 | 開始されました | Raymond James | Strong Buy |
| 2026-03-05 | 開始されました | Wedbush | Outperform |
| 2026-02-13 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | William Blair | Outperform |
| 2025-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Robert W. Baird | Outperform |
| 2025-06-06 | 開始されました | Oppenheimer | Outperform |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Climb Bio Inc (CLYM) 最新ニュース
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com Canada
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio Appoints Breanna O’Reilly to Board - TipRanks
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Nigeria
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com India
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Value Benchmark - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio, Inc. Actuals & Estimates (NASDAQ:CLYM) - TradingView
NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients - Traders Union
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Climb Bio stock price target reiterated at $20 by H.C. Wainwright - Investing.com UK
CLYM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Climb Bio stock price target reiterated at $20 by H.C. Wainwright By Investing.com - Investing.com India
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLYM Q1 2026 Earnings: Narrower-than-expected loss highlights progress despite no revenueEarnings Revision Downgrade - dars.gov.et
CLYM News | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Climb Bio Inc (CLYM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Climb Bio Inc (CLYM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Climb Bio Inc (CLYM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Surprise Stocks - newsline.com
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM) - The Globe and Mail
Climb Bio Inc (CLYM) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):